THE WOODLANDS, Texas--(BUSINESS WIRE)--Opexa Therapeutics, Inc. (NASDAQ:OPXA), a company involved in the development and commercialization of cell therapies, today announced the formation of a Clinical Advisory Board (CAB) to help guide the Company’s clinical development strategy for its autologous monocyte-derived islet (MDI) transplantation therapy for diabetes mellitus, a technology based on Opexa’s adult human stem cell platform.
